title: A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases.
abstract: OBJECTIVE
  Small-cell carcinoma is a variant of poorly differentiated neuroendocrine carcinoma. Primary small-cell carcinoma of the cervix (SCCC) is recognised as a rare and aggressive malignant tumour with poor prognosis. In this study, the authors report 25 Chinese cases of SCCC, with a particular focus on their clinical and pathological characteristics.
  
  
  METHODS
  The records of 25 patients from 4075 Chinese patients with cervical cancer were collected and reviewed, including the patients' age, initial symptoms, cervical tumour size, International Federation of Gynaecology and Obstetrics clinical stage, lymph-node metastasis, treatments and follow-up results. Immunohistochemical detection was performed for cytokeratin, epithelial membrane antigen, neuron-specific enolase (NSE), synaptophysin (Syn), chromogranin A (CgA), neuronal cell adhesion molecules (CD56), thyroid transcriptional factor-1 and S100 protein (S100).
  
  
  RESULTS
  The median age of 25 patients with SCCC was 43.7 years. The most common symptom was abnormal vaginal bleeding. Histologically, there were 19 'homogenous' SCCC samples and six samples of SCCC mixed with adenocarcinoma. The proportion of SCCC samples with positive immunoreactivity were 100.0% for NSE, 96.0% for Syn, 68.0% for CD56, 76.0% for CgA, 40.0% for thyroid transcriptional factor-1, 84.0% for epithelial membrane antigen, 68.0% for cytokeratin and 8.0% for S100, respectively. Every patient received one to three types of treatments, including surgery, chemotherapy and radiotherapy. The median survival time of patients was 20.9 months after diagnosis.
  
  
  CONCLUSIONS
  The higher proportion of positive labelling of Syn, CD56, CgA, and NSE in SCCC implicated that they are valuably applied in a differential diagnosis of the malignancy. The patients with SCCC receive one to three types of therapies, including surgery, chemotherapy and radiotherapy, and have a poor prognosis.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou, PR China.
authors.forename: Jun-Dong
authors.initials: JD
authors.lastname: Li
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhuang
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Li
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: Feng
authors.forename: Jin-Hui
authors.initials: JH
authors.lastname: Hou
authors.forename: Liang
authors.initials: L
authors.lastname: Chen
authors.forename: An-Na
authors.initials: AN
authors.lastname: Zhu
authors.forename: Qiu-Liang
authors.initials: QL
authors.lastname: Wu
authors.forename: Jing-Ping
authors.initials: JP
authors.lastname: Yun
mesh_terms: D000328:Adult; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D055815:Young Adult